Biotech

The Medicines Company Reports First Quarter 2013 Financial Results

PARSIPPANY, NJ: 23% Increase in Net Revenue to $156 Million ...

Thallion Delays Annual Meeting Date

MONTREAL, QUEBEC: ...

Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends

PISCATAWAY, NJ: ...

Vista Partners Updates Coverage on Mast Therapeutics, Inc.; Price Target $4.50

SAN FRANCISCO, CA: Currently Enrolling Patients in Phase 3 Sickle Cell Clinical Trial, Phase 2 ALI Clinical Trial Scheduled to Commence by Q1 2014 ...

Atossa Genetics to Present at FSX San Francisco Investor Conference

SEATTLE, WA: ...

Acura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013

PALATINE, IL: ...

Brain Tumour Targeting Team Awarded Additional Funding

TORONTO, ONTARIO: ...

TiGenix : Positive Phase IIa Study Results in Refractory Rheumatoid Arthritis With Allogeneic Stem Cell Product Cx611

LEUVEN, BELGIUM: TiGenixReports Positive Phase IIa Study Results in Refractory Rheumatoid Arthritis With Allogeneic Stem Cell Product Cx611; Management Will Conduct a Conference Call to Discuss the Results Today at 4p ...

Critical Outcome Technologies Inc. Presenting at the 2013 Bio International Convention

LONDON, ONTARIO: Dr. Danter to Participate in Round Table Discussion with Gates Foundation ...

Ceapro Reports Full-Year 2012 Financial and Operating Results

EDMONTON, ALBERTA: ...